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BCG: DO WE HAVE AN ALTERNATIVE*?
C.N. Paramasivan, Daniel Herbert and R. Prabhakar
Vaccination is generally used as a form of
immunoprophylaxis, so that administration of the
vaccine even a long time before exposure to the
wild-type infectious organism should afford
protection. Since effector T and B cells are short-
lived; a prime requisite for a vaccine is to
generate immunological memory1. In the case of
organisms such as mycobacteria which are obligate
intracellular pathogens and which elicit
granulomatous tissue reactions, artificial
immunisation with live bacteria is required to
induce protection.2,3 The only existing vaccine
against tuberculosis is the BCG (Bacille Calmette
- Guerin), an attenuated strain of M. bovis, and
it is mandatory or officially recommended in 182
countries or territories. Under the Expanded
Programme on Immunisation (EPI), started by the
Government of India in 1978, BCG is
recommended to be given to all infants 3-9
months after birth.4
HISTORY OF BCG VACCINE
The history of BCG vaccine and the trials
conducted to assess its effectiveness in humans
have been reviewed by many workers.5-10 BCG,
the bile-tolerant, attenuated strain of M. bovis,
was isolated by Calmette and Guerin.11 Ox-bile
was originally added to these cultures to prevent
clumping of bacilli. This led to the fortuitous
observation that growth in the presence of bile
also resulted in attenuation or gradual loss of
virulence. Such attenuated organisms multiply
only to a limited extent in the animal or human
body and can bring about an increase in the
resistance of the host to a subsequent fully
virulent infection by the same or other antigenically
closely related organisms. Calmette further
attenuated this strain by cultivation of the organism
on a potato-glycerol-bile medium for 230 serial
transfers between the years 1908 and 1918.
The bacilli resulting from this attenuation
have never been cloned. The original strain of
BCG has been lost and has been replaced by a
variant while it was being transferred serially on
artificial culture media at the Pasteur Institute12.
It has since been maintained by many different
laboratories, using many different methods. As
a result, the BCG strains used today are not
bacteriologically identical.13,14 In 1966, a WHO
Expert Committee on Biological Standardisation
adopted a series of recommendations for the
production of  BCG vaccine. 1 5  These
recommendations stated that the vaccine should
be freeze-dried, and that the vaccine strain should
be maintained by the seed-lot-system whereby no
vaccine is produced from a seed more than 12
passages removed from the primary freeze-dried
lot. Such a method of maintenance was soon
adopted by most laboratories and this eliminated
the possibility of more attenuated variants in later
BCG vaccine lots.16
BCG VACCINE PRODUCTION IN INDIA
In India, the BCG Vaccine Laboratory was
started in Guindy, Madras in 1948 for the
production of BCG vaccine for use in India and
also for supply to some of the neighbouring
countries. Since 1966, Danish strain 1331 is
being used here for the preparation of both the
liquid and the freeze-dried BCG vaccines, based
on the seed-lot-system”.
For preparing the liquid and freeze-dried
vaccines, the BCG Laboratory, Madras, uses the
method followed at the State Serum Institute,
Copenhagen, but using Sauton potato medium for
maintaining the BCG strain. The prepared vaccine
is tested for purity by Ziehl Neelsen smear for
acid fast bacilli, and by culture on nutrient broth,
thioglycolate medium and Sabouraud’s Agar
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medium. Total bacterial count and the number
of culturable particles in the preparation are
estimated. Biological tests are carried out in
guinea pigs to estimate the degree of virulence
of the BCG vaccine, allergenicity and safety. In
addition to the above tests, in the case of the
freeze-dried vaccine, tests are carried out to
estimate residual moisture and heat stability.
Both types of vaccines are to be stored at
refrigeration temperature, protected from light.
Under these conditions of storage, the liquid
vaccine can be used for 4 weeks from the date
of manufacture while the freeze-dried vaccine
can be used for 3 months.
BCG can be administered intracutaneously,
orally, by scarification or by multiple punctures.
The most widely used method of administration
is by intracutaneous injection. The dose is usually
0.1 ml and the site of injection is the upper arm.
In the newborn, the dose used is 0.05 ml. The
Madras liquid BCG vaccine administered by an
intracutaneous injection of 0.1 ml of the vaccine
contains 0.075 mg (moist weight) of BCG. The
freeze-dried vaccine prepared there is reconstituted
by the addition of sterile distilled water or sterile
saline to contain 0.1 mg (moist weight) in 0.1
ml of vaccine which is given intracutaneously.
EFFICACY OF BCG -VACCINE
BCG was used successfully in humans for
the first time in 1921 by Weil-Halle, a colleague
of Calmette and Guerin. 18 Scepticism concerning
the safety and efficacy of BCG vaccine, and the
Lubeck disaster in which 72 of 240 children
vaccinated with BCG died as a result of being
fed a batch of vaccine containing virulent tubercle
bacilli, delayed the acceptance of BCG. A series
of controlled trials was begun in the 1930s.
Despite inconsistent results from the trials, WHO
encouraged widespread dissemination of BCG
vaccines, starting in the 1950s.7 By the 1970s
BCG became the most widely used vaccine in
the world. About 3 billion doses have been given
in the last four decades, and more than 70 per
cent of the world children now receive BCG.5,19
Between the years 1935 and 1955, at least
eight controlled trials were conducted to assess
the efficacy of BCG vaccine against tuberculosis.
Table: Protective efficacy of BCG vaccine
against tuberculosis (trials between 1935 to
1955)
Population
group
Period of Protective
intake efficacy
(%)
North American Indians 1 9 3 5 - 1 9 3 8  8 0
Chicago infants 1 9 3 7 - 1 9 4 8  7 5
Georgia school children 1947 0
Illinois children 1 9 4 7 - 1 9 4 8  0
Puerto Rico population 1 9 4 9 - 1 9 5 1  3 1
Georgia and Alabama 1950 14
population
British children 1 9 5 0 - 1 9 5 2  7 8
South Indian 1 9 5 0 - 1 9 5 5  3 1
rural population
The protective efficacy results obtained ranged
from 0 to 80 per cent (Table).8
THE SOUTH INDIAN TRIAL
A new study was started in Chingleput,
south India, in 1968 in an attempt to avoid the
methodological errors that might have affected
previous trials.10,20,21 This south Indian BCG trial
was organised by the Indian Council of Medical
Research (ICMR) in collaboration with the WHO
and Centres for Disease Control (CDC), US
Public Health Services. The intake for the study
started in 1968 and was completed in 1971,
including about 2,60,000 participants out of a
population of 3,60,000. The entire population of
all ages was eligible and tuberculin reactors were
not excluded, in contrast with previous trials.
Two BCG strains, Copenhagen and Paris, were
tested at two doses, 0.1 mg and 0.01 mg. Neither
of the vaccines, whether in full or reduced
dosage, gave any protection against the bacillary
form of pulmonary tuberculosis, as assessed over
a 7.5 year follow up period. No data were
available from the study to evaluate protection
in children. Very little disease was observed in
the period immediately after infection.22 Incidence
peaks were absent in young children and in young
adults but the incidence increased logarithmically
with age.
The findings of the south Indian trial were
disappointing. The ICMR convened an expert
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committee meeting to scrutinise the trial
methodology, wherein it was agreed that no errors
in the conduct of the field operations or in the
data processing could have been SO serious as to
invalidate the results.
10 In the first meeting of the
ICMR/WHO Scientific Group23 it was stated that
be data obtained in this trial were unique and
of great importance for tropical countries, and
should be considered as the starting point for
further intensive investigations into the
epidemiological, bacteriological and immunological
problems related to BCG vaccine and tuberculosis,
as well as studies to test certain hypotheses, e.g,
that the immune response of the population was
unusual, that the vaccines were inadequate to
confer immunity, that the south Indian variant of
M. tuberculosis acted as an attenuated immunising
agent, and that mycobacteria other than M.
tuberculosis may have partially immunised the
study population.
EXPLANATIONS FOR VARYING
EFFICACY OF BCG
The explanations and hypotheses for the
varying efficacy of BCG have been discussed in
detail5,7. BCG’s varying efficacy due to interactions
with the immune responses to other mycobacterial
infections still remains one of the most popular
explanations. Palmer and associates24,25 showed in
animal experiments, and in studies of US navy
personnel, that infections with certain non-
tuberculous mycobacteria could impart some
protection against infection with the tubercle
bacillus and such naturally acquired protection
could mask any protection due to BCG vaccination,
partially or totally. This explanation was criticised
by Hart26 as being inadequate to explain all the
differences between the various BCG vaccine
trials. Comstock et al27 also could not find any
evidence for lowered protection by BCG in those
with intermediate levels of tuberculin reactivity,
and this was thought to be due to non-tuberculous
mycobacterial infection, in the Puerto Rico trial.
In the 1980s, Rook, Stanford and
associates28-30 proposed that exposure to non-
tuberculous mycobacteria (NTM) can result in
two types of cell-mediated responses, the ‘Listeria
type' and the ‘Koch type’. Which of these two
types of responses is evoked depended, among
other factors, on the mycobacterial species inducing
the response and the immunomodulating cells
and the pathway brought into play. They further
proposed that the ‘Listeria type’ of response
enhances the protective effect of subsequent
vaccination with BCG while the ‘Koch type’
response opposes the protective effect of BCG.
Once Koch-like responsiveness is present, this
blocks subsequent recognition of further species
by Listeria-like responses. BCG vaccination of
a person with a pre-existing Koch-like response
will temporarily boost this response, but completely
fail to reconvert to Listeria-like responsiveness
or induce protection from pathogenic challenge.
According to them, this is likely to have been
the situation in the south Indian trial.31,32
Investigations carried out since then have
been able to produce some evidence supporting
the hypothesis that infection with NTM induces
a protective response and does not interfere with
the immunity produced by BCG. Attempts to
demonstrate that prior infection with any of the
mycobacteria induced a suppressive effect against
BCG have failed.33-36
The study population in the south Indian
BCG trial was characterised by a very high
prevalence of nonspecific sensitivity.37 Further,
nearly 20 per cent of the NTM obtained from
sputum samples of subjects in this area belonged
to the Mycobacterium avium-intracellulare-
scrofulaceum (MAIS) complex.38 And a recent
study on the isolation profiles of environmental
mycobacteria present in soil, water and dust
samples, and sputum samples of symptomatics
in this area has shown that isolates belonging to
the MAIS complex are predominant in water,
dust and sputum samples while organisms of the
M. fortuitum complex are predominant in soil
samples.39
The hypothesis that oral immunisation with
M. avium intracellulare complex might induce
tolerance which might interfere with the immune
response to subsequent BCG immunisation was
studied at the Tuberculosis Research Centre
(TRC)40 in guinea pigs challenged with M.
tuberculosis, and it was found that there was no
interference with the protective immunity induced
by BCG. A later study using intradermal route
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showed that while there was no interference with
the immunity due to BCG by prior exposure to
NTM on the early course of challenge infection,
modulation could be taking place during the later
course.41
The variation in the efficacy of BCG has
also been attributed to the differences between
the BCG preparations42,43. Another view is that
BCG is more effective in stopping haematogenous
spread of the bacteria as occurring in primary
progressive disease and endogenous reactivation
compared with exogenous reinfections.44 Other
explanations include the genetic or physiological
differences between the trial populations.
More recently, another explanation for the
varying efficacy of BCG has been proposed based
on the observation that a subgroup of the population
may actually be adversely affected by vaccination.45
Several trials included many subjects with weak
initial tuberculin sensitivity, due either to
environmental mycobacterial infection or to
infection with M. tuberculosis. While it is accepted
that vaccine efficacy may be moderately reduced
in the former subgroup, it has been postulated
that the latter subgroup may be at risk of
reactivation of tuberculosis soon after vaccination
perhaps from focal reactions due to enhancement
of their weak sensitivity. The low levels of
efficacy in several trials, and the early adverse
effect in the south Indian trial are broadly
consistent with this hypothesis.
In the search for identifying the correlates
of vaccine-induced protective immunity, more
than 70,000 subjects in northern Malawi were
skin tested with soluble antigens of the tubercle
and leprosy bacilli, and then followed up for 5
years for tuberculosis and leprosy incidence.
Incidence rate ratios were calculated to compare
subjects with different levels of prior skin test
sensitivity.46 It was found that the delayed type
hyper-sensitivity to mycobacterial antigens has
different implications for tuberculosis and leprosy:
low level hypersensitivity, probably attributable
to environmental mycobacteria, was associated
with protection, but persistent vaccine-associated
hypersensitivity to mycobacterial antigens was
not a correlate of vaccine-derived protection
against mycobacterial diseases.
BCG VACCINATION AND
HIV INFECTION
With regard to BCG vaccination in NIV
infected individuals, there are reports of BCG
abscesses in HIV seropositives, and of disseminated
infection due to BCG in at least one case given
BCG.47 However, in all these cases, the resulting
infection could be successfully treated. Since the
risks and known consequences of natural infection
with tubercle bacilli are likely to be more serious
than the risks associated with live attenuated
vaccines, the WHO has recommended that all
asymptomatic HIV infected children should receive
the standard vaccines, both live and inactivated,
and those with symptoms of AIDS Related
Complex (ARC)/AIDS should receive all the
vaccines but BCG. However, in developing
countries like India, where extensive HIV testing
is not possible, the WHO Expert Group has
recommended that all infants should continue to
receive immunisation against all the major
preventable diseases.48
There is no evidence that BCG activates
HIV infection.49 Further, it has been observed that
the incidence of disease due to M. avium
intracellulare (MAI) in AIDS patients varies
from region to region and it has been postulated
that this difference is the result of a protective
effect of neonatal BCG vaccination.50 In the
USA, 30 per cent of patients with AIDS develop
MAI disease in contrast to only 10 per cent of
AIDS patients in Sweden. This difference in
incidence between the two countries could be due
to BCG vaccination: most Swedish patients with
AIDS would have received BCG in infancy while
those in the USA would be unvaccinated. This
is further supported by the fact that over 50 per
cent of AIDS patients in Netherlands, where BCG
vaccination is not given, developed disease due
to MAI or M. Scrofulaceum Also, in a limited
follow up of HIV infected individuals at the TRC,
Madras, it has been found that while a few HIV
infected individuals developed disease due to M.
tuberculosis, no case has been encountered so far
with disease due to MAI (Tuberculosis Research
Centre - unpublished observations). It has been
suggested that MAI disease in AIDS is not due
to direct infection but that it arises from long
standing silent foci of MAI in the lymphatic
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tissue of the patient. 51 It is possible that neonatal
BCG vaccination prevents overt infection by
MAI and may, therefore, prevent inapparent
persisting infection of lymphoid tissue, thus
removing the internal reservoir of these bacilli
from which AIDS-related MAI disease may arise
later in life.52
BCG AS AN IMMUNOPOTENTIATING
AGENT
The widespread use  of  BCG has
demonstrated its safety and its potent
immunogenicity. This has also led to its suggested
use as a carrier to vaccination against other
diseases.53-54 BCG and other mycobacteria are
highly effective adjuvants. It is one of the few
vaccines that can be given at birth, and with a
single dose it induces long-lasting immune
responses. Till now, nearly 3 billion vaccinations
have been carried out using BCG with a long
record of safe use. There is also a worldwide
distribution network with experience in BCG
vaccination. The adjuvant properties of BCG and
its cell wall components have previously been
made use of in experimental vaccines. Mixtures
of BCG and schistosomal antigens have been
used successfully to protect mice in a model of
schistosomiasis.55 Mixture of muramyl dipeptide,
which is one of the mycobacterial ceil wall
components that contributes to the adjuvant
properties, and killed simian immunodeficiency
virus (SIV) has been shown to provide partial
protection against SIV infection in monkeys.56
Mixtures of BCG and killed M. leprae have been
used in large scale trials to assess the efficacy
Of this leprosy vaccine candidate.57
RECOMBINANT BCG AND BCG AS A
MULTIPLE VACCINE VEHICLE
Recently developed genetic engineering
techniques for mycobacteria have provided the
means for the introduction and expression of
foreign genes in BCG.53-58 Recombinant BCG
vaccine vehicles can induce immune responses
to foreign proteins produced by the bacillus,
indicating that BCG can act simultaneously as
an adjuvant and as a vehicle to produce and
deliver specific antigens to the immune system.
A BCG recombinant may provide a longer lasting
immunity to a pathogen than a simple mixture
of BCG and the antigen because the antigen
continues to be produced by BCG multiplying in
the host.
There is no ready answer to the question
whether there is an alternative to BCG vaccine
for protection against tuberculosis. It is possible
to improve the protective efficacy of the existing
BCG vaccine against tuberculosis by using the
tools of genetic engineering even though very
little has been achieved in this direction to date.
Such an approach requires a full understanding
of the important factors in the virulence of M.
tuberculosis, pathogenesis of tuberculosis, and
protective response against tuberculosis. Genetic
deletion or modification of mycobacterial virulence
factors or the addition of appropriate mycobacterial
antigens, important for protection, might improve
the effectiveness of BCG as an antituberculosis
vaccine.
CONCLUSION
Fine and Rodrigues7 state that several factors,
especially the differences in BCG strains and
regional differences in mycobacterial ecology in
addition to differences in trial methods, have all
contributed to the observed variation in BCG’s
efficacy. They conclude that despite our inability
to predict its precise effect, BCG is still judged
worthwhile in many countries because there is
a possibility that the vaccine might provide
reasonable levels of protection against childhood
forms of the disease in most populations.7 Recent
retrospective studies of BCG vaccine efficacy
among newborns and children have reported a
protective effect against all forms of tuberculosis
ranging from. 17 to 90 per cent. And protection
against tuberculous meningitis and cavitary, miliary
and bone and joint tuberculosis has been estimated
to be 75 per cent or greater.59-61 BCG vaccination,
when effective, does not prevent infection but
interferes with the haematogenous spread of
tubercle bacilli, thus reducing the risk of severe
primary disease and its complications.60 A meta-
analysis of 14 trials and 12 case-control studies
showed that the protective effect of BCG against
tuberculosis was 51 and 50 per cent respectively.62
Combining data from 7 trials reporting on deaths
from tuberculosis, the relative risk for death
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among the vaccinated was
effect). Five case-control
0.29 (71% protective
studies reporting on
tuberculous meningitis showed a 64 per cent
protective effect, and 3 case-control studies
reporting efficacy of BCG in preventing
disseminated tuberculosis showed a 78 per cent
protective effect. The conclusion was that BCG
reduces the risk of active tuberculosis on an
average by 50 per cent, and the risk of
tuberculosis death, meningitis and disseminated
tuberculosis. The fact that BCG provides variable
though significant protection against leprosy
increases its value in countries with high prevalence
of leprosy.63
BCG vaccination alone, at least with the
the present vaccine, cannot substantially
influence the epidemiological situation but
should still’ be continued for children because
its use is justified.64 BCG vaccination of the
newborns protects against the serious forms of
tuberculosis, is safe and cheap, and should be
used in developing countries, including India,
where tuberculosis is more prevalent. However,
in such highly endemic areas, due to the frequent
occurrence of exogenous reinfection and also due
to the waning of protective effect over the years
after vaccination, BCG vaccination of the newborns
may not offer protection in the later years of life
when revaccination, perhaps at the school going
age, may have to be considered. In developed
countries with low prevalence of tuberculosis,
BCG should be given to high risk groups such
as immigrants, their newborns, contacts of patients
with tuberculosis and hospital staff.65
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